MBX Biosciences, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | — | $79.2M | $57.4M | $28.5M |
| SG&A Expense | — | $18.9M | $10.8M | $6.8M |
| Operating Income | — | $-98.1M | $-68.2M | $-35.3M |
| Operating Margin | — | — | — | — |
| Interest Expense | — | — | — | — |
| Pretax Income | — | $-87.0M | $-61.9M | — |
| Income Tax Expense | — | $0 | $0 | $0 |
| Net Income | — | $-87.0M | $-61.9M | $-32.6M |
| Net Margin | — | — | — | — |
| EPS (Basic) | — | $-2.38 | $-1.94 | $-1.07 |
| EPS (Diluted) | — | $-2.38 | $-1.94 | $-1.07 |
| Shares Outstanding (Basic) | 47.5M | 36.5M | 31.9M | 30.6M |
| Shares Outstanding (Diluted) | 47.5M | 36.5M | 31.9M | 30.6M |
| Dividends Per Share | — | — | — | — |